Highest-materiality recent filing
Lipella Pharmaceuticals files Chapter 11, sells substantially all assets to XRAIY LLC
Filed Chapter 11 on March 30, 2026 in Western District of Pennsylvania.
Lipella Pharmaceuticals files Chapter 11 bankruptcy, plans 363 sale process
Filed voluntary Chapter 11 petition in Western District of Pennsylvania on March 30, 2026.
All 27 patients completed 4-week treatment; no serious adverse events reported.
Lipella Pharmaceuticals Delisted from Nasdaq, Plans to Relist on National Exchange
Delisted from Nasdaq effective June 19, 2025 due to non-compliance with Listing Rules 5100, 5635, and 5640 regarding private placement transactions.
Lipella Pharmaceuticals receives Nasdaq delisting; stock moves to OTC Markets
Nasdaq Hearings Panel determined to delist Lipella common stock effective June 20, 2025; trading suspended.
Lipella receives Nasdaq deficiency notice for preferred stock issuance; faces potential delisting
Nasdaq notified Lipella that its Series C Preferred Stock and Warrant issuances violated Listing Rules 5635(d) and 5640 (shareholder approval and voting rights).
Lipella presents positive Phase 2a data for LP-310; 0.50mg dose shows stat-sig efficacy in OLP
Statistically significant improvements at 0.50mg dose: IGA from 3.42 to 1.71 (p=0.007), REU from 26.91 to 11.88 (p=0.003).
Lipella Pharmaceuticals regains Nasdaq equity compliance after $5.9M placement
Final closing of Series B convertible preferred stock offering on March 12, 2025; net proceeds ~$5.9M.
Lipella Pharma enters $2.64M ATM equity facility with H.C. Wainwright
ATM agreement for up to $2,641,881 of common stock at market prices.
Lipella completes final close of Series B offering ($88.5K) and launches March warrant offering
Final close sold 885 shares of Series B preferred at $100/share for $88,500 gross; net proceeds $73,455.
Lipella raises $3.79M in third closing of Series B convertible preferred offering
Sold 37,880 Series B convertible preferred shares at $100 each; gross proceeds $3.788M, net $3.124M after fees.
Lipella Pharmaceuticals amends placement agent agreement with Spartan Capital Securities
Second Amendment removes at-the-market facility restrictions and modifies tail provision to require 10% fee on investments from accredited retail investors within one year of termination.
FDA approved Expanded Access Program for LP-310 (oral rinse for OLP) on Feb 6, 2025.
Nasdaq grants Lipella continued listing with conditions; compliance deadline April 14, 2025
Received Nasdaq Hearings Panel decision on Jan 10, 2025 granting continued listing subject to interim milestones.
Lipella Pharmaceuticals closes $2.23M initial tranche of Series B preferred offering
Initial closing of $2.23M on Dec 23, 2024: 22,295 Series B shares sold at $100 each.
Lipella Pharmaceuticals enters agreement for up to $6M Series B convertible preferred offering
Offering of up to $6,000,000 in Series B non-voting convertible preferred stock; underwritten by Spartan Capital Securities.
Lipella Pharmaceuticals effects 1-for-8 reverse stock split
Reverse split effective Nov 7, 2024; every 8 shares converted to 1 share.
Lipella announces 1-for-8 reverse split effective Nov 7 to meet Nasdaq bid price
Reverse stock split ratio of 1-for-8; effective 5:00 p.m. ET on November 7, 2024.
Lipella receives Nasdaq delisting notice for equity deficiency; hearing set for Dec 12
Nasdaq notified Lipella of delisting for stockholders' equity of $1.7M, below $2.5M minimum.
Lipella receives Nasdaq delisting notice; equity $1.7M vs $2.5M minimum
Nasdaq notified Lipella on Aug 21, 2024 of non-compliance with $2.5M minimum stockholders' equity requirement.
Total offering of 2,066,000 equity units (399K shares + 1,667K pre-funded warrants) at $0.62 per unit.
Lipella receives Nasdaq bid price deficiency notice; 180 days to cure
Nasdaq letter dated April 17, 2024, notes LIPO common stock closing bid price below $1.00 for 30 consecutive business days.
Lipella believes it meets Nasdaq minimum equity rule after $2M private placement
Private placement closed Oct 25, 2023; gross proceeds $2.0M, net ~$1.7M.
Lipella receives Nasdaq deficiency notice for potential minimum equity violation
Received Nasdaq notice on Nov 21, 2023, for failure to maintain minimum $2.5M stockholders' equity as of Sep 30, 2023.
Lipella raises $2M via private placement of pre-funded warrants and warrants
Gross proceeds ~$2M from sale of 1,315,790 pre-funded warrants (exercise $0.001) and 1,315,790 warrants (exercise $1.40) at $1.519/unit.
Completed Phase 2a trial of LP-10 for hemorrhagic cystitis; top-line results showed no serious adverse events and reduced symptoms.
Lipella reports positive Phase 2a results for LP-10 in hemorrhagic cystitis
All 13 subjects tolerated LP-10 without product-related serious adverse events.
Effective June 17, 2023, the board of directors (the “Board”) of Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), pursuant to its powers under the Company’s second amended and restated by-laws, appointed Dr. Lori Birder as a member of the Board.
On May 30, 2023, Dr. David Battleman informed the board of directors, or the Board, of Lipella Pharmaceuticals Inc. (the “Company”) that he will resign from the Board, effective June 17, 2023.
On March 21, 2023, the board of directors (the “Board”) of Lipella Pharmaceuticals Inc., a Delaware corporation (the “Company”), pursuant to its powers under the Company’s second amended and restated by-laws, appointed Daniel Cohen as a member of the Board, thereby increasing the Board membership count to seven (7).
Max materiality 1.00 · Median 0.60 · Most common event other_material